






LEUKEMIA &  
LYMPHOMA  
SOCIETY®

# Therapy Acceleration Program®

Portfolio Assets in Institutional Sponsored Trials  
Blood Cancer Development



Therapy	Target/Modality	Indications	Preclinical	Phase 1	Phase 2	Phase 2 Reg / Phase 3
CAR-37	T Cell Therapy	B-cell lymphoma/ T-cell lymphoma		 MASSACHUSETTS GENERAL HOSPITAL		
NK-cells + ALT-803	NK Cell Therapy	Heme malignancies		 CASE WESTERN RESERVE UNIVERSITY EST. 1826		
K-NK003	NK Cell Therapy	AML		 IST		
Fimepinostat	HDAC/PI3K small molecule	Lymphoma (pediatric)		 IST		
Pinometostat + Aza or SOC	DOT1L small molecule	MLL leukemia		 IST		

IST: investigator-sponsored trial

Updated October 2020